Clinical Trials Logo

Kidney Tubular Necrosis, Acute clinical trials

View clinical trials related to Kidney Tubular Necrosis, Acute.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT02563366 Not yet recruiting - Clinical trials for Kidney Transplantation

Effect of BM-MSCs on Early Graft Function Recovery After DCD Kidney Transplant.

Start date: November 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This study is designed to investigate whether allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs) can promote function recovery in patients with poor early graft function after kidney transplantation from Chinese Donation after Citizen Death (DCD). DCD kidney transplant recipients with poor early graft function (with or without dialysis) post transplant are equally randomized into MSCs group or control group. Patients in MSCs group are administered MSCs treatment. Allogeneic BM-MSCs (1*10^6/kg) from third party are given intravenously for four consecutive doses every week after enrollment. Patients in control group receive placebo. Renal allograft function (eGFR), rejection, patient/graft survival and severe adverse events up to 12 months post enrollment are monitored.

NCT ID: NCT02561767 Not yet recruiting - Clinical trials for Kidney Transplantation

Effect of BM-MSCs in DCD Kidney Transplantation

Start date: October 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This study is designed to determine the efficacy and safety of allogeneic bone marrow-derived mesenchymal stem cells in kidney transplantation from Chinese donation after citizen's death (DCD). A pair uremia patients receiving kidney grafts from a same donor are randomized into two groups: MSCs group and control group. Besides routine induction therapy (ATG or Basiliximab) and maintenance immunosuppressive drugs (low-dose Tacrolimus + MPA + prednisone), patients in MSCs group are administered MSCs treatment (1*10^6/kg). Allogeneic bone marrow-derived MSCs (1*10^6/kg) are given intravenously at day 0 (post renal reperfusion during surgery), day 7, day 14 and day 21. The renal allograft function, rejection, patient/graft survival and severe adverse events within 12 months post-transplant are monitored.